Dyslipidemia

Using relevant clinical trial data, investigators created a price tag of about $6300 annually for the very effective, often costly inhibitor.

Steven Nissen, MD, discusses the updates to the cholesterol guidelines and how the risk calculator should not be considered an end-all be-all.

“These guidelines bring back the concept of adjusting therapy for cholesterol levels, and they recommend more aggressive treatment targets for people in very high risk,” said Cleveland Clinic’s Steven Nissen.

Fish oil or fish for CV protection? It's a well studied yet unresolved question. Highlights, here, of the ASCEND study and all those that came before. 

In addition to a 25% reduction of risk of future cardiovascular events, icosapent ethyl (Vascepa) lowered the risk of cardiovascular death by 20%.

Ezetimibe 10 mg/day significantly reduced the incidence of atherosclerotic cardiovascular events in elderly patients with high LDL cholesterol compared to control.

The updated cholesterol guidelines continue to emphasize a healthy lifestyle for people of all ages and the need for personalized treatment plans. They also lay out a path for escalating treatment when statins aren’t sufficient.

A South Korea meta-analysis found that, similarly to C. difficile, tuberculosis risk could be limited by the lipid-lowering agent.

The Eluvia stent system was approved based on data from the IMPERIAL non-inferiority trial, which compared Eluvia to Zilver PTX.

The capsules of icosapent ethyl, which is derived from fish, showed a 25% relative risk reduction compared to placebo.

Obstructive sleep apnea negatively impacts lipid levels, greatly increasing risk for CV disease and independent of obesity, according to the largest analysis of the link to date.

Though previous research showed telemonitoring and pharmacist consultation helped patients manage blood pressure for about one year, researchers have been unsure whether it would provide sustained, long-term benefits in at-risk patients.

Patients administered the FDA-approved therapy reported tripled rates of weight-loss, along with noninferiority for risk of major cardiovascular events, over 1 year and an extension period.

Compared to those with LDL cholesterol levels 160 mg/dL had a 70-90% increased risk.

Medical nutrition therapy for hyperlipidemia management is widely recommended by clinical guidelines. Is it cost-effective?

The optimal duration of dual antiplatelet therapy remains unclear, despite being proven efficacious for roughly 2 decades.

The paradigm of obesity is complex and requires a multi-disciplinary approach, but it is one of the most gratifying experiences for both the physicians and patient when they see the results of weight loss.

The Cleveland Clinic’s pioneer of minority programs plans to end health disparity.

AF is associated with major disease burden, predominately in the form of cardiovascular comorbidities. As a direct oral anti-coagulant, rivaroxaban has been a proven inhibitor of ischemic stroke risks in patients with AF.

Trials of valbenazine for TD do not find that the treatment adds to cardiovascular disease risks associated with schizophrenia or the cardiovascular complications of antipsychotics.

How some of the most recent trial analysis narrows the clinical scope of GLP-1 and SGLT-2 targeting therapies.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

IgE for alpha-gal was identified in 26% of the patients, and plaque buildup was 30% higher in those patients compared to those that were not sensitized.

Today, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 12-8 in favor of approval of volanesorsen (Waylivra) for the treatment of familial chylomicronemia syndrome (FCS).

From fruit juice to fibrates to fluvastatin, what do you know about the safety of specific statin interactions?